S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Bed Bath & Beyond Is Circling the Drain
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA Price Target & Analyst Ratings

$51.91
-1.47 (-2.75%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$50.14
$54.20
50-Day Range
$41.13
$53.38
52-Week Range
$37.59
$79.50
Volume
132,009 shs
Average Volume
145,700 shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.88

Enanta Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$65.88
26.90% Upside
High Prediction$96.00
Average Prediction$65.88
Low Prediction$49.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$65.88$66.00$76.29$95.29
Predicted Upside26.90% Upside34.24% Upside23.45% Upside18.82% Upside
Get Enanta Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.


ENTA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ENTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Enanta Pharmaceuticals Stock vs. The Competition

TypeEnanta PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.57
2.65
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside26.90% Upside1,300.19% Upside8.10% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/27/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$50.00 ➝ $49.00-4.87%
12/9/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$56.00+33.46%
11/24/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$50.00+11.11%
11/22/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Roy Buchanan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$96.00+119.48%
11/22/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Perform$65.00 ➝ $54.00+16.38%
7/6/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$62.00+17.69%
5/19/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$130.00 ➝ $90.00+95.78%
5/11/2022Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$101.00 ➝ $70.00+35.92%
10/6/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$95.00+55.23%
1/29/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral$44.00 ➝ $55.00+19.36%
8/25/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$87.00+71.80%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ENTA Price Target - Frequently Asked Questions

What is Enanta Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Enanta Pharmaceuticals stock is Moderate Buy based on the current 3 hold ratings and 4 buy ratings for ENTA. The average twelve-month price prediction for Enanta Pharmaceuticals is $65.88 with a high price target of $96.00 and a low price target of $49.00. Learn more on ENTA's analyst rating history.

Do Wall Street analysts like Enanta Pharmaceuticals more than its competitors?

Analysts like Enanta Pharmaceuticals less than other Medical companies. The consensus rating for Enanta Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ENTA compares to other companies.

Does Enanta Pharmaceuticals's stock price have much upside?

According to analysts, Enanta Pharmaceuticals's stock has a predicted upside of 35.32% based on their 12-month price targets.

What analysts cover Enanta Pharmaceuticals?

Enanta Pharmaceuticals has been rated by HC Wainwright, JMP Securities, Oppenheimer, Royal Bank of Canada, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ENTA) was last updated on 2/2/2023 by MarketBeat.com Staff